Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN – Get Free Report)’s share price crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.06 and traded as high as $0.0695. Enzon Pharmaceuticals shares last traded at $0.0650, with a volume of 222,300 shares.
Enzon Pharmaceuticals Price Performance
The firm has a market cap of $4.82 million, a price-to-earnings ratio of -1.30 and a beta of 0.20. The business has a 50-day moving average of $0.05 and a 200-day moving average of $0.06.
About Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.
Featured Articles
- Five stocks we like better than Enzon Pharmaceuticals
- Energy Security Is Now National Security – Positioning Is Happening Now
- The gold chart Wall Street is terrified of…
- Have $500? Invest in Elon’s AI Masterplan
- Your Bank Account Is No Longer Safe
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Enzon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
